CB1 (cannabinoid receptor type 1) neurons represent one of the most abundant neuronal populations in the mammalian brain, expressing the highest density of G protein-coupled receptors (GPCRs) in the central nervous system. These neurons play a critical role in modulating synaptic transmission through retrograde signaling mechanisms, making them essential regulators of neural circuit function and plasticity.
| Property |
Value |
| Category |
Receptor neurons |
| Primary Receptor |
CB1 (encoded by CNR1 gene) |
| Neurotransmitter |
Endocannabinoids (2-AG, anandamide) |
| Signal Transduction |
Gi/o protein-coupled inhibition of adenylate cyclase |
| Brain Regions |
Basal ganglia, cerebellum, hippocampus, cortex, hypothalamus |
| Expression Pattern |
Presynaptic terminals (axonal), some somatic |
The CB1 receptor is a Class A GPCR encoded by the CNR1 gene located on chromosome 6q14-q15. The receptor consists of:
- Seven transmembrane domains spanning the postsynaptic membrane
- N-terminal extracellular domain involved in ligand binding
- C-terminal intracellular domain coupled to Gi/o proteins
¶ Endocannabinoid Ligands
CB1 receptors are activated by endogenous cannabinoids (endocannabinoids):
| Ligand |
Full Name |
Synthesis |
Primary Action |
| 2-AG |
2-Arachidonoylglycerol |
DAGL-mediated cleavage of membrane phospholipids |
Full agonist |
| AEA |
Anandamide (N-arachidonoylethanolamine) |
NAPE-PLD enzymatic synthesis |
Partial agonist |
Upon activation, CB1 receptors couple to Gi/o proteins leading to:
- Inhibition of adenylate cyclase → reduced cAMP production
- Activation of MAPK pathways (ERK1/2, p38, JNK)
- Modulation of ion channels (inhibition of N-type Ca2+ channels, activation of A-type K+ channels)
- PI3K/Akt pathway activation
CB1 neurons mediate a unique form of retrograde synaptic transmission:
- Postsynaptic depolarization triggers calcium influx
- 2-AG is synthesized and released retrogradely
- Presynaptic CB1 receptors are activated
- Presynaptic release is inhibited (glutamate or GABA)
- Signal terminates via FAAH (anandamide) and MAGL (2-AG) hydrolysis
| Brain Region |
CB1 Function |
Behavioral Output |
| Hippocampus |
Modulates LTP/LTD, memory formation |
Learning and memory |
| Basal Ganglia |
Regulates dopamine release, motor control |
Movement initiation |
| Cerebellum |
Controls Purkinje cell function |
Motor coordination |
| Cortex |
Regulates pyramidal neuron activity |
Cognitive processing |
| Hypothalamus |
Modulates appetite, energy homeostasis |
Feeding behavior |
The endocannabinoid system has bidirectional relationship with seizure activity:
- CB1 agonists and cannabidiol (CBD) have demonstrated antiepileptic properties
- FDA-approved CBD formulations (Epidiolex) for Lennox-Gastaut and Dravet syndromes
- Endocannabinoid dysfunction may contribute to seizure generation
- CB1 receptor expression is altered in epileptic hippocampus
CB1 neurons play complex roles in AD pathogenesis:
- CB1 receptor loss correlates with disease progression in AD brains
- Endocannabinoid signaling modulates amyloid-beta (Aβ) toxicity
- CB1 agonism may provide neuroprotection through anti-inflammatory mechanisms
- Memory deficits in AD may involve impaired CB1-mediated synaptic plasticity
In PD, CB1 receptors interact with dopaminergic systems:
- CB1/D2 receptor heteromers have been identified in the striatum
- CB1 antagonists may improve motor function in PD models
- Endocannabinoid levels are elevated in PD patients
- CB1 modulation affects levodopa-induced dyskinesias
CB1 neurons contribute to neuroinflammation regulation:
- CB1 activation reduces inflammatory cytokine production
- Myelin repair may be modulated by endocannabinoid signaling
- Spasticity is reduced by CB1 agonists (THC, nabilone)
| Drug |
Application |
Mechanism |
| Dronabinol |
HIV/AIDS anorexia, chemotherapy nausea |
CB1 full agonist |
| Nabilone |
Chemotherapy-induced nausea |
Synthetic THC analog |
| CBD |
Epilepsy (Lennox-Gastaut, Dravet) |
FAAH inhibitor, CB1 negative allosteric modulator |
| Drug |
Application |
Status |
| Rimonabant |
Obesity (withdrawn) |
CB1 inverse agonist |
| TM38837 |
Obesity/metabolic disorders |
Peripherally-restricted CB1 antagonist |
- Peripherally-restricted CB1 antagonists for metabolic diseases
- CB1 positive allosteric modulators for neuroprotection
- FAAH/MAGL inhibitors to elevate endocannabinoid levels
- CB1-CB2 heteromer-selective compounds
- Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003 Nov;4(11):873-84.
- Howlett AC, et al. cannabinoid receptor classification. Pharmacol Rev. 2002 Sep;54(2):161-202.
- Kano M, et al. Retrograde signaling at cerebellar synapses. Nat Rev Neurosci. 2009 Mar;10(3):223-33.
- Zhornitsky S, et al. Cannabidiol in epilepsy: The efficacy and safety of Epidiolex. Pharmaceuticals. 2019 Sep;12(4):140.
- Bedse G, et al. Therapeutic targeting of the endocannabinoid system in Alzheimer's disease. Front Pharmacol. 2019 May;10:507.
- Martinez-Marignacci M, et al. Cannabinoid receptors in Parkinson's disease. J Parkinsons Dis. 2015;5(4):909-21.
- Hebert-Chatelain E, et al. A cannabinoid link to memory. Nature. 2014 Aug;514(7521):S66-9. Available from:
- Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov. 2009 Jan;8(1):17-23.
CB1 receptor expression follows a characteristic pattern across brain regions:
Highest Expression:
- Cerebellum (molecular layer interneurons)
- Basal ganglia (striatum, globus pallidus)
- Hippocampus (CA1, CA3 strata radiatum and lacunosum-moleculare)
- Cerebral cortex (layers II-III, V-VI)
Moderate Expression:
- Hypothalamus (preoptic area, paraventricular nucleus)
- Amygdala (central, basolateral nuclei)
- Thalamus (mediodorsal, intralaminar nuclei)
Lower Expression:
- Brainstem (dorsal raphe, locus coeruleus)
- Spinal cord (dorsal horn)
- Presynaptic terminals: Primary location on axon terminals
- Somatic: Lower density on cell bodies
- Dendritic: Present on dendritic shafts and spines
- Glial: Astrocytic expression also documented
CB1 receptor expression develops progressively:
- Embryonic stage: Early expression in neural progenitor cells
- Prenatal: Gradual increase in specific brain regions
- Postnatal: Peak expression during adolescence
- Adult: Stable expression with regional variation
- Aging: Declining CB1 density in hippocampus and cortex
- Neuronal migration: Endocannabinoid gradients guide migrating neurons
- Axonal guidance: CB1 signaling directs axon pathfinding
- Synaptogenesis: Regulates formation of excitatory and inhibitory synapses
- Myelination: Influences oligodendrocyte differentiation
| Method |
Information Gained |
| Radioligand binding ([3H]CP55,940) |
Receptor density, affinity |
| Immunohistochemistry |
Cellular and subcellular localization |
| In situ hybridization |
CNR1 mRNA distribution |
| Conditional knockout |
Cell-type specific function |
| Cre-lox recombination |
Circuit-specific manipulation |
- CNR1-/- mice: Constitutive knockout, developmental compensation
- CNR1flox/flox mice: Conditional knockout flexibility
- ** reporter mice | Circuit mapping |
- **Disease models | AD, PD, epilepsy models |
- Aβ oligomers reduce CB1 receptor density
- CB1 activation reduces Aβ-induced toxicity
- FAAH inhibition (elevating AEA) protects against Aβ
- Tau pathology correlates with CB1 loss
- CB1 agonists may reduce tau phosphorylation
- Endocannabinoid dysregulation in tauopathies
- CB1 activation has anti-inflammatory effects
- Reduces microglial activation
- Modulates cytokine production
- Endocannabinoids have antioxidant properties
- CB1 agonists protect against oxidative damage
- Mitochondrial CB1 contributes to neuroprotection